Cannasouth Limited

Equities

CBD

NZCBDE0009S6

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. Other stock markets 07:00:00 2024-03-24 pm EDT			5-day change	1st Jan Change
0.098 ^NZD	+2.08%		-.--%	-26.32%

Apr. 15	Cannasouth Terminates COO	MT
Apr. 11	New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	MT

Cannasouth Limited Announces Consolidated Earnings Results for the Six Months Ended 30 June 2019

August 27, 2019 at 04:35 am EDT

Cannasouth Limited announced consolidated earnings results for the six months ended 30 June 2019. For the six months, the company reported interest income of NZD 18,987. Loss after tax from continuing operations was NZD 821,175.

Latest news about Cannasouth Limited

Cannasouth Terminates COO	Apr. 15	MT
New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	Apr. 11	MT
Cannasouth CEO Resigns	Apr. 10	MT
Cannasouth Enters Voluntary Administration, CFO Resigns	Mar. 28	MT
Cannasouth Extends Trading Halt, Mulls Restructuring Options	Mar. 27	MT
Cannasouth Shares Placed on Trading Halt	Mar. 25	MT
Cannasouth Limited Reports Revenue Results for the Month of December 2023	Jan. 22	CI
Cannasouth Issues NZ$1.1 Million Convertible Bonds	Dec. 21	MT
Cannasouth Raises Over NZ$2 Million from Sale of Shares, Bonds	Dec. 12	MT
Cannasouth Limited acquired Eqalis Group New Zealand Limited from Eqalis shareholders.	23-05-29	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Cannasouth Limited signed a binding term sheet to acquire Eqalis Group New Zealand Limited from Eqalis shareholders for NZD 44.4 million.	22-12-18	CI
Cannasouth Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-10	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Cannasouth Limited completed the acquisition of remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	21-11-29	CI
Cannasouth Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2021	21-08-30	CI
Cannasouth Limited completed the acquisition of remaining 40% stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin.	21-08-01	CI
Cannasouth Limited signed an agreement to acquire remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	21-07-03	CI
Cannasouth Limited agreed to acquire remaining 40% of stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin for NZD 1 million.	21-07-03	CI
Cannasouth Limited Approves Election of Christine Pears as Non-Executive Independent Director	21-07-01	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	21-03-29	CI
Cannasouth Limited Announces Unaudited Earnings Results for the Year Ended December 31, 2020	21-02-24	CI
Cannasouth Limited Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-27	CI

Chart Cannasouth Limited

Duration

Period

More charts

Company Profile

Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANNASOUTH LIMITED	-26.32%	19.8M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research